Skip to main content

Table 3 Age at treatment initiation and treatment durations of NIV and LTOT

From: The prevalence of non-invasive ventilation and long-term oxygen treatment in Helsinki University Hospital area, Finland

Years (mean ± SD) All patients COPD NMD RCWD OHS ILD Misc*
Age at NIV initiation 58.7 ± 15.5 68.8 ± 7.9 46.9 ± 18.3 57.9 ± 17.3 59.8 ± 11.5 62.8 ± 7.8 52.2 ± 17.7
Age at LTOT initiation 71.0 ± 12.0 72.0 ± 8.2 73.4 ± 17.5 65.3 ± 19.3 67.3 ± 9.2 73.5 ± 13.5 70.2 ± 15.9
NIV-treatment duration** 7.0 ± 5.0 5.3 ± 3.5 8.4 ± 6.9 11.4 ± 7.2 6.5 ± 3.4 6.1 ± 2.8 6.4 ± 4.5
LTOT-treatment duration** 4.9 ± 4.2 5.1 ± 3.3 5.6 ± 5.3 7.8 ± 6.4 6.0 ± 3.6 3.4 ± 3.1 4.7 ± 5.6
Lifetime of deceased patients (N = 368) 75.4 ± 11.5 77.4 ± 8.1 61.4 ± 16.8 77.4 ± 13.5 72.2 ± 8.7 77.0 ± 1.8 76.7 ± 12.6
  1. NIV, non-invasive ventilation; LTOT, long-term oxygen treatment; COPD, chronic obstructive pulmonary disease; NMD, neuromuscular disease; RCWD, restrictive chest wall disease; OHS, obesity hypoventilation syndrome; ILD, interstitial lung disease; Misc, miscellaneous
  2. *Misc includes heart disease and cancer patients
  3. **Treatment duration until 1.1.2021 or death